Wenxin Xu, MD

Medical Oncology

Wenxin Xu, MD

Dr. Xu received his MD from Harvard Medical School in 2014. He completed residency training in internal medicine at Beth Israel Deaconess Medical Center, followed by fellowship training in hematology and medical oncology also at Beth Israel Deaconess Medical Center. Dr. Xu joined the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute in 2020. In addition to caring for patients, Dr. Xu also conducts clinical research seeking to improve the treatment and outcomes of patients with genitourinary cancers.

View full Profile

Related Videos

Wenxin (Vincent) Xu, MD presents a potential biomarker (KIM-1) Video

Wenxin (Vincent) Xu, MD presents a potential biomarker (KIM-1)

Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.

Kidney Cancer Highlights from ESMO 2023 Video

Kidney Cancer Highlights from ESMO 2023

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ESMO 2023.

ASCO 2023: Kidney Cancer Highlights Presented By Vincent (Wenxin) Chu, MD Video

ASCO 2023: Kidney Cancer Highlights Presented By Vincent (Wenxin) Chu, MD

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2023.

Kidney Cancer Highlights from ESMO 2022 Video

Kidney Cancer Highlights from ESMO 2022

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the genitourinary cancer clinical updates you need to know from ESMO 2022

Analysis of Plasma KIM-1 as a Biomarker for Recurrence Risk After Resection for Localized Renal Cell Carcinoma Video

Analysis of Plasma KIM-1 as a Biomarker for Recurrence Risk After Resection for Localized Renal Cell Carcinoma

Kidney cancer research: Analysis of plasma KIM-1 as a biomarker for recurrence risk after resection for localized renal cell carcinoma, presented by Vincent Wenxin Xu, MD at ASCO #GU21 abstract 342

Kidney Cancer Conference Highlights from ASCO GU 2024 Video

Kidney Cancer Conference Highlights from ASCO GU 2024

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO GU 2024.

Kidney Cancer Conference Highlights from ASCO 2022 Video

Kidney Cancer Conference Highlights from ASCO 2022

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2022.